株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

大腸がん診断薬・治療薬の世界市場 - 成長・動向・予測

Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 353905
出版日 ページ情報 英文 113 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.21円で換算しております。
Back to Top
大腸がん診断薬・治療薬の世界市場 - 成長・動向・予測 Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年04月01日 ページ情報: 英文 113 Pages
概要

当レポートでは、世界の大腸がん向け診断薬および治療薬の市場について分析し、市場の基本構造や最新情勢、主な市場促進・抑制要因、市場規模の動向見通し (今後6年間分)、モダリティ (診断/治療法別) および地域別の詳細動向、市場競争の動き (各種資本取引など)、主要企業のプロファイルといった情報を取りまとめてお届けいたします。

第1章 イントロダクション

第2章 分析手法

第3章 エグゼクティブ・サマリー

第4章 市場のダイナミクス

  • 市場概要
  • 市場促進要因
  • 市場抑制要因
  • ポーターのファイブフォース分析

第5章 市場区分

  • モダリティ (手法) 別
    • 診断法
      • 検便
      • 免疫組織化学 (IHC)
      • 大腸内視鏡検査
      • 軟性S字結腸鏡検査
      • その他の診断法
    • 治療法
      • 化学療法
        • 代謝拮抗剤
          • フルオロウラシル
          • カペシタビン
        • アルキル化剤
          • オキサリプラチン
        • その他
      • 免疫療法
        • ベバシズマブ
        • セツキシマブ
        • パニツムマブ
      • がん防御物質
      • その他
  • 地域別
    • 北米 (米国、カナダ、メキシコなど)
    • 欧州 (ドイツ、英国、フランス、イタリア、スペインなど)
    • アジア太平洋地域 (中国、日本、インド、オーストラリア、韓国など)
    • 中東・アフリカ (湾岸協力会議 (GCC) 諸国、南アフリカなど)
    • 南米 (ブラジル、アルゼンチンなど)

第6章 競争環境

  • 企業プロファイル
    • Abbott Laboratories
    • Amgen Inc.
    • Clinical Genomics
    • EDP Biotech
    • Epigenomics AG
    • F. Hoffmann-La Roche AG
    • Novigenix SA
    • Quest Diagnostics
    • Sanofi SA
    • Siemens Healthineers
    • VolitionRX

第7章 市場機会と将来動向

目次
Product Code: 50590

Market Overview

The colorectal cancer diagnostics and therapeutics market are expected to register a CAGR of nearly 4.6% during the forecast period, 2019-2024.

  • Colorectal cancer has one of the largest incidence and prevalence rates, worldwide. Primary causes of colorectal cancer are said to be lifestyle disorders, ageing, and diet.
  • According to the World Health Organization (WHO), an increase of around 70% is expected in the colorectal cancer cases across the world, by 2030.
  • Therefore, high incidence and prevalence rates are the primary factors, driving the market studied.
  • According to a research article published in 2016, "Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the United States".
  • Colorectal cancer (CRC) is estimated to account for over 9% of all cancer incidences and is a major cause of morbidity and mortality throughout the world. CRC is the second-most-common cause of cancer-related deaths in the United States.

Scope of the Report

Colorectal cancer, also known as bowel cancer, colon cancer, or rectal cancer, and is any form of cancer that affects the colon and the rectum. The report tracks revenue generated by therapeutics used for the management of colorectal cancer, along with various screening tests, kits, and medical devices used for the diagnosis of colorectal cancer.

Key Market Trends

Immunotherapy Blockbusters to Remain a Significant Revenue Source For Leading Players Due to Label Expansions Despite Approaching Patent Expiry.

Bevacizumab (Avastin) is a monoclonal antibody that prevents tumors from growing in blood vessels, by antagonizing vascular endothelial growth factor (VEGF), which is a substance released by tumors to stimulate new blood vessel formation. The FDA approved a labeling extension for bevacizumab, administered in combination with intravenous 5-fluorouracil-based chemotherapy, for the second-line treatment of metastatic carcinoma of the colon or rectum. The approval of cyramza (ramucirumab) for second-line Avastin pre-treated metastatic setting, in 2016, is expected to propel the growth of the colorectal cancer drugs market, in the future.

The United States is Expected to Retain Largest Market Share During the Forecast Period

Geographically, the United States holds the largest market share with respect to demand and revenue. In 2017, 39,910 new rectal cancer cases and 95,520 new colon cancer cases were reported in the United States based on the estimates by the American Cancer Society. These estimates indicate that colorectal cancer is increasing its prevalence in the United States, which is in turn, leading to the growth of the market. The Asia-Pacific is also expected to witness a strong growth pattern in the coming years, with China and India showing rapid progress. In 2015, Roche signed an agreement with an insurance company in Shenzhen City. The Chinese people were among the first few to approve Avastin for reimbursement. This is expected to increase access to colorectal cancer therapeutics in China.

Competitive Landscape

Several large drug and equipment manufacturers exist within the global colorectal cancer diagnostic and therapeutics market. Moreover, several new biotech firms are also active in the therapeutics segment. Key players in the market include Abbott Laboratories, Beckman Coulter, Clinical Genomics, Companion DX, EDP Biotech, Epigenomics AG, F. Hoffmann-La Roche AG, Novigenix, Quest Diagnostics, Siemens Healthineers, and VolitionRX, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technological Advancements in Radiology and Chemotherapy
    • 4.2.2 Increasing Incidence and Prevalence of Colorectal Cancer
  • 4.3 Market Restraints
    • 4.3.1 High Costs Associated with Drugs
    • 4.3.2 Side Effects Associated With Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Modality
    • 5.1.1 Diagnostics Techniques
      • 5.1.1.1 Stool Tests
      • 5.1.1.2 Immunohistochemistry
      • 5.1.1.3 Colonoscopy
      • 5.1.1.4 Flexible Sigmoidoscopy
      • 5.1.1.5 Other Diagnostics Techniques
    • 5.1.2 Therapeutics
      • 5.1.2.1 Chemotherapy
      • 5.1.2.1.1 Antimetabolites
      • 5.1.2.1.1.1 Fluorouracil
      • 5.1.2.1.1.2 Capecitabine
      • 5.1.2.1.2 Alkylating Agent
      • 5.1.2.1.2.1 Oxaliplatin
      • 5.1.2.1.3 Other Chemotherapeutic Agents
      • 5.1.2.2 Immunotherapy
      • 5.1.2.2.1 Bevacizumab
      • 5.1.2.2.2 Cetuximab
      • 5.1.2.2.3 Panitumumab
      • 5.1.2.3 Chemoprotectant
      • 5.1.2.4 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East & Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East & Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Amgen Inc.
    • 6.1.3 Clinical Genomics
    • 6.1.4 EDP Biotech
    • 6.1.5 Epigenomics AG
    • 6.1.6 F. Hoffmann-La Roche AG
    • 6.1.7 Novigenix SA
    • 6.1.8 Quest Diagnostics
    • 6.1.9 Sanofi SA
    • 6.1.10 Siemens Healthineers
    • 6.1.11 VolitionRX

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top